Cargando…
Carbamylation reduces the capacity of IgG for hexamerization and complement activation
Carbamylation is a post‐translational modification that can be detected on a range of proteins, including immunoglobulin (Ig)G, in several clinical conditions. Carbamylated IgG (ca‐IgG) was reported to lose its capacity to trigger complement activation, but the mechanism remains unclear. Because C1q...
Autores principales: | Lubbers, R., Oostindie, S. C., Dijkstra, D. J., Parren, P. W. H. I., Verheul, M. K., Abendstein, L., Sharp, T. H., de Ru, A., Janssen, G. M. C., van Veelen, P. A., van den Bremer, E. T. J., Bleijlevens, B., de Kreuk, B.‐J., Beurskens, F. J., Trouw, L. A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7066385/ https://www.ncbi.nlm.nih.gov/pubmed/31853959 http://dx.doi.org/10.1111/cei.13411 |
Ejemplares similares
-
Complement is activated by elevated IgG3 hexameric platforms and deposits C4b onto distinct antibody domains
por: Abendstein, Leoni, et al.
Publicado: (2023) -
The isotype and IgG subclass distribution of anti-carbamylated protein antibodies in rheumatoid arthritis patients
por: van Delft, Myrthe A. M., et al.
Publicado: (2017) -
Anti-carbamylated protein antibodies precede disease onset in monkeys with collagen-induced arthritis
por: Verheul, Marije K., et al.
Publicado: (2017) -
IL4‐10 fusion protein: a novel immunoregulatory drug combining activities of interleukin 4 and interleukin 10
por: Steen‐Louws, C., et al.
Publicado: (2018) -
DuoHexaBody-CD37(®), a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies
por: Oostindie, Simone C., et al.
Publicado: (2020)